<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02799862</url>
  </required_header>
  <id_info>
    <org_study_id>IOM-110333</org_study_id>
    <nct_id>NCT02799862</nct_id>
  </id_info>
  <brief_title>Nab-Paclitaxel in Combination With Carboplatin as First-line Therapy in Patients With NSCLC</brief_title>
  <acronym>NEPTUN</acronym>
  <official_title>A Non-interventional Study of Nab-paclitaxel (Abraxane速) in Combination With Carboplatin as First Line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NEPTUN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>iOMEDICO AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>iOMEDICO AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-arm non-interventional study (NIS) to evaluate the effectiveness, safety and
      quality of life (QoL) in patients with advanced NSCLC receiving the combination of
      nab-paclitaxel and carboplatin as first line palliative therapy in a real life setting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present NIS is designed to provide additional knowledge in terms of effectiveness, safety
      and quality of life in routine administration of the combination of nab-paclitaxel
      (Abraxane速) and carboplatin as first line treatment for adult patients with locally advanced
      or metastatic non-small cell lung cancer (NSCLC) who are not candidates for potentially
      curative surgery and / or radiation therapy. The combination of Abraxane速 and carboplatin has
      been approved in Europe in March 2015 based on results from a pivotal randomized, open label
      phase III study with 1,052 patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS) rate</measure>
    <time_frame>After 6-months</time_frame>
    <description>Effectiveness in terms of PFS will be assessed and evaluated according to local medical standards from screening until end of treatment observation (6 months). Additional survival and and if applicable clinical PFS will be followed up for 24 months post-treatment observation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Overall Survival (OS)</measure>
    <time_frame>After 6-months</time_frame>
    <description>Effectiveness in terms of OS will be assessed and evaluated according to local medical standards from screening until end of treatment observation (6 months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>After 6-months</time_frame>
    <description>Effectiveness in terms of ORR will be assessed and evaluated according to local medical standards from screening until end of treatment observation (6 months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Adverse events (AEs)</measure>
    <time_frame>through study completion, an average of 9 months</time_frame>
    <description>Safety assessments will consist of monitoring of all AEs, including serious adverse events, and monitoring of laboratory values. AEs will be graded according to CTCAE V4.03. Supportive therapies will be documented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported outcomes on Quality of Life</measure>
    <time_frame>Baseline, after 6 weeks, after 3 months, every 3 months throughout study completion, an average of 9 months</time_frame>
    <description>Questionnaires: EQ5D-5L and FACT-L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rationale for physicians' treatment decision</measure>
    <time_frame>Baseline</time_frame>
    <description>Rationale for physicians' treatment decision, assessed with a therapy-decision questionnaire</description>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-Paclitaxel</intervention_name>
    <description>Nab-Paclitaxel will be administered in accordance with the SmPC of Nab-Paclitaxel.</description>
    <other_name>Abraxane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin will be administered as combination partner of Nab-Paclitaxel in accordance with SmPC of Nab-Paclitaxel.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with locally advanced / metastatic NSCLC who are not candidates for
        potentially curative surgery and / or radiation therapy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed diagnosis of locally advanced / metastatic, unresectable
             NSCLC

          -  According to SmPC

        Exclusion Criteria:

          -  According to SmPC
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tobias Dechow, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oncology Ravensburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sophie Koszinowski</last_name>
    <phone>+49 761 15242</phone>
    <phone_ext>0</phone_ext>
    <email>neptun@iomedico.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>iOMEDICO</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-W端rttemberg</state>
        <zip>79108</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Koszinowski</last_name>
      <phone>+49-761-15242</phone>
      <phone_ext>0</phone_ext>
      <email>neptun@iomedico.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>van Warmerdam LJ, Rodenhuis S, ten Bokkel Huinink WW, Maes RA, Beijnen JH. The use of the Calvert formula to determine the optimal carboplatin dosage. J Cancer Res Clin Oncol. 1995;121(8):478-86.</citation>
    <PMID>7642691</PMID>
  </reference>
  <reference>
    <citation>Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, Hon JK, Hirsh V, Bhar P, Zhang H, Iglesias JL, Renschler MF. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol. 2012 Jun 10;30(17):2055-62. doi: 10.1200/JCO.2011.39.5848. Epub 2012 Apr 30.</citation>
    <PMID>22547591</PMID>
  </reference>
  <reference>
    <citation>Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015 Mar;65(2):87-108. doi: 10.3322/caac.21262. Epub 2015 Feb 4.</citation>
    <PMID>25651787</PMID>
  </reference>
  <reference>
    <citation>Reck M, Popat S, Reinmuth N, De Ruysscher D, Kerr KM, Peters S; ESMO Guidelines Working Group. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014 Sep;25 Suppl 3:iii27-39. doi: 10.1093/annonc/mdu199. Epub 2014 Aug 11.</citation>
    <PMID>25115305</PMID>
  </reference>
  <reference>
    <citation>Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 2001 Sep;37(13):1590-8. Review.</citation>
    <PMID>11527683</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2016</study_first_submitted>
  <study_first_submitted_qc>June 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2016</study_first_posted>
  <last_update_submitted>November 8, 2017</last_update_submitted>
  <last_update_submitted_qc>November 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic</keyword>
  <keyword>locally advanced</keyword>
  <keyword>unresectable</keyword>
  <keyword>NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

